medigraphic.com
ISSN 1029-3019 (Electronic)

2015, Number 08

<< Back Next >>

MediSan 2015; 19 (08)

Importance of weight lost in patients with obesity

Pereira DOL, Palay DMS

Language: Spanish
References: 30
Page: 1043-1050
PDF size: 479.66 Kb.


ABSTRACT

In spite of the advances in the clinical and epidemiological knowledge on obesity, its prevalence has increased significantly, and its prevention and treatment continue to be a challenge for the health professionals. At present it is considered that the control of the energy balance is based on a feedback system which objective is to maintain the stable energy deposits, in order to achieve, with the decrease of weight, important benefits in terms of health and life quality. In this work, some considerations related to the etiopatogenicity of obesity and the importance of weight reduction in the obese patients are exposed.


REFERENCES

  1. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 2005; 332: 621-8.

  2. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. N Engl J Med. 2006; 322: 1483-7.

  3. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000; 404: 661-71.

  4. Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med. 2003; 54: 453-71.

  5. Pi-Sunyer X. A clinical view of the obesity problem. Science. 2003; 299: 859-60.

  6. Bouchard C, Perusse L. Genetics of obesity. Annu Rev Nutr. 1993; 13: 337-54.

  7. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. N Engl J Med. 2006; 322: 1483-7.

  8. Barsh GS, Farooqi IS, O’Rahilly S. Genetics of body-weight regulation. Nature. 2000; 404: 644-51.

  9. Bray GA. Progress in understanding the genetics of obesity. J Nutr. 2007; 127(Suppl 5): 940-2.

  10. Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagnon YC, Bouchard C. The human obesity gene map: the 2001 update. Obes Res. 2002; 10: 196-243.

  11. Jacobson P, Ukkola O, Rankinen T, Snyder EE, Leon AS, Rao DC, et al. Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort. J Clin Endocrinol Metab. 2002; 87: 4442-6.

  12. Bray GA, Popkin BM. Dietary fat intake does affect obesity! Am J Clin Nutr. 2008; 68: 1157-73.

  13. Plagemann A, Harder T, Franke K, Kohlhoff R. Long-term impact of neonatal breast-feeding on body weight and glucose tolerance in children of diabetic mothers. Diabetes Care. 2002; 25: 16-22.

  14. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril. 2005; 63: 516-21.

  15. Rossner S. Obesity: the entity of the XXI century. Int J Obesity. 2002; 26(Suppl 4): 2-4.

  16. Mather KJ, Steinberg HO, Baron AD. Weight loss and endothelial function in obesity. Diabetes Care. 2003; 26(6): 1927-8.

  17. Fantuxxi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9.

  18. Domínguez Reyes CA. Adiponectina: El tejido adiposo más allá de la reserva inerte de energía. Rev Endocrinol Nutr. 2007 [citado 17 Jun 2015]; 15(3).

  19. James P, Rigby N. Estrategias radicales para prevenir la obesidad y la diabetes. Diabetes Voice. 2004 [citado 17 Jun 2015]; 49(2).

  20. Sierra Ariza ID. Hacia el manejo práctico de la diabetes mellitus tipo 2. 2 ed. Bogotá: Novo Nordisk; 2005.

  21. Vasudevan AR, Ballantyne C. et al. Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus. Clin Cornerstone. 2005; 7(2-3): 7-16.

  22. Rodríguez Porto AL, Sánchez León M, Martínez Valdés LL. Síndrome metabólico. Rev Cubana Endocrinol. 2002 [citado 17 Jun 2015]; 13(3).

  23. Cho E, Rimm EB, Stampfer MJ, Willet WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002; 40: 954-60.

  24. Villar Álvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J, Ortega Sánchez-Pinilla R, Vilaseca Canals J, et al. Guía de prevención cardiovascular en atención primaria. Barcelona: SEMFYC; 2003. p. 15-20.

  25. Solís Villanueva J. Industria alimentaria y diabesidad. Lima: ALAD; 2007.

  26. Masana L, Redón J. Visión integrada del paciente con riesgo cardiovascular. Madrid: Ergón; 2003. p. 117.

  27. Alfonzo Guerra JP. Obesidad. Epidemia del siglo XXI. La Habana: Editorial Científico-Técnica; 2008. p. 53.

  28. González Juanatey JR, Grigorian Shamagian L, Juiz Crespo MA, Sánchez Loureiro M, Rodríguez Moldes E, Dopico Pita J, et al. Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-diabetes. Rev Esp Cardiol. 2008; 61(11): 1168-77.

  29. Arpa Gámez A, González Sotolongo O, Roldós Cuza E, Borges Helps A, Acosta Vaillant R. El síndrome metabólico como factor de riesgo para la disfunción endotelial. Rev Cubana Med Mil. 2007 [citado 17 Jun 2015]; 36(1).

  30. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006; 47(10): 1919-26.




2020     |     www.medigraphic.com